<?xml version="1.0" encoding="UTF-8"?>
<p>Four patients (3 on boceprevir and 1 on telaprevir) discontinued treatment early due to adverse events felt most likely related to Peg-IFN/RBV. Two patients (one in each treatment group) experienced mood disturbances while two patients on boceprevir experienced nausea, vomiting and flu-like symptoms. Treatment tolerability data are presented in 
 <xref rid="pone.0163945.t002" ref-type="table">Table 2</xref>.
</p>
